Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults

Exclusion criteria

• . Participants with COVID-19, diagnosed by rapid antigen test and/or RT-PCR for SARS-CoV-2;
• . Previous contact with individuals diagnosed with COVID-19 within 14 days prior to screening;
• . Vaccination against influenza and/or COVID-19 within 7 days prior to the study;
• . Presence of gastrointestinal symptoms and/or dyspnea associated with cold or flu symptoms;
• . Clinical history consistent with bacterial upper respiratory tract infection requiring antibiotic therapy;
• . History of grade II or III septal deviation, nasal polyps, marked turbinate hypertrophy, adenoid hypertrophy, chronic sinusitis (or recent episode within the last 2 weeks), rhinitis (seasonal allergic, drug-induced, vasomotor, atrophic, or other), or other conditions causing nasal obstruction;
• . Diagnosis of: congenital glucose-6-phosphate dehydrogenase deficiency, prothrombin deficiency, gastroduodenal ulcer, hepatic porphyria, narrow-angle glaucoma, chronic nephritis, blood dyscrasias, asthma, chronic respiratory infection, chronic respiratory disease, severe cardiocirculatory conditions, or immunocompromised status;
• . History of hypersensitivity to analgesics, antirheumatic drugs, and/or alcoholic beverages;